Amphion Innovations plc
Directors Receive Shares in Lieu of Fees
London and New York, 6 December 2011 - Amphion Innovations plc (the “Company”) (LSE: AMP), the developer of medical and technology businesses, announces that the Company has today issued 159,228 ordinary shares, representing 0.11% of the enlarged issued share capital, to certain of its Board members as their directors’ fees for the third quarter to 30 September 2011, priced at 5.13p, being the average of the closing mid-market price for the five days leading up to the market close on 30 September 2011. Following this issue, the directors’ shareholdings in the Company are as follows:
|R. James Macaleer||109,228||23,427,247||17.37%|
Director, Anthony Henfrey waived his fees for the third quarter of 2011.
Admission of the 159,228 new ordinary shares, ranking pari passu with the existing ordinary shares, is expected on 12 December 2011. Following this allotment the total issued share capital of the Company will increase to 134,848,552 ordinary shares with each share holding one voting right.
The Company has today granted options in respect of a further 7,250,000 Ordinary Shares at an issue price of 4 pence per Ordinary Share to certain employees and Directors which shall be exercisable from 31 December 2013 under the terms of the Share Option Scheme. This will include options in respect of 2,000,000 Ordinary Shares granted to Richard Morgan bringing his total options to 2,500,000 Ordinary Shares, 2,000,000 Ordinary Shares granted to Robert Bertoldi bringing his total options to 2,350,000 Ordinary Shares, and 1,750,000 Ordinary Shares granted to Jerel Whittingham bringing his total options to 2,000,000 Ordinary Shares. As of 1 July 2011, 6,500,000 options under the scheme expired, including 2,000,000 issued to Richard Morgan, 1,250,000 issued to Robert Bertoldi, and 1,750,000 issued to Jerel Whittingham.
For further information please contact
+1 212 210 6224
Seymour Pierce Limited
Freddy Crossley/ Mark Percy
+44 020 7107 8300
+44 020 7930 0777
About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com